

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Anti-CD8 antibody [SP239]

RRID:AB_2756374

Type: Antibody

Proper Citation

Abcam Cat# ab178089, RRID:AB_2756374

Antibody Information

URL: http://antibodyregistry.org/AB_2756374

Proper Citation: Abcam Cat# ab178089, RRID:AB_2756374

Target Antigen: CD8

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-P

Antibody Name: Anti-CD8 antibody [SP239]

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: SP239

Antibody ID: AB_2756374

Vendor: Abcam

Catalog Number: ab178089

Alternative Catalog Numbers: M5390

Record Creation Time: 20250819T220007+0000

Record Last Update: 20250820T004730+0000

Ratings and Alerts

No rating or validation information has been found for Anti-CD8 antibody [SP239].

No alerts have been found for Anti-CD8 antibody [SP239].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Melero I, et al. (2026) Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 528.

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer research communications, 5(6), 1049.

Solomon BJ, et al. (2025) The Impact of the Tumor Microenvironment on the Effect of IL-1 ? Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer research communications, 5(4), 632.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. Cell reports, 44(11), 116526.

Xu M, et al. (2025) Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment. Journal of gastrointestinal oncology, 16(4), 1366.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. Cell reports. Medicine, 5(5), 101550.

Gong C, et al. (2024) Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. Cell reports. Medicine, 5(11), 101807.

Zhao J, et al. (2024) Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer. Med (New York, N.Y.), 5(8), 981.

Li J, et al. (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer cell, 41(6), 1152.

Aggarwal C, et al. (2023) Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous

Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(3), 560.

Gong C, et al. (2023) Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. iScience, 26(6), 106720.

Wang J, et al. (2022) Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(13), 2865.

Zheng KF, et al. (2021) PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. Translational lung cancer research, 10(12), 4617.

Halbrook CJ, et al. (2019) Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell metabolism, 29(6), 1390.